Skip to main content
TipRanks
Go Ultimate75% OFF

International Stem Cell (ISCO) AI Stock Analysis

45 Followers
ISCO

International Stem Cell

(Other OTC:ISCO)

Select Model
Rating:39Underperform
Price Target:$0.13â–¼(-16.98% Downside)
Action:downgraded
Date:02/04/26

ISCO's overall stock score of 39 is primarily driven by weak financial performance, with persistent losses, negative cash flows, and high leverage posing significant risks. Valuation concerns due to a negative P/E ratio further weigh on the score, while neutral technical indicators provide limited support.

Positive Factors
Gross margin sustainabilityConsistently high gross margins indicate the company’s products/services have durable unit economics. That margin buffer supports gross profitability even with volatile revenue, giving management room to invest in R&D or sales while pursuing a path to operating leverage if top-line stabilizes.
Negative Factors
Weak balance sheetRepeated periods of negative equity and materially fluctuating debt create financial fragility. That weak capitalization reduces flexibility to fund R&D or scale, raises refinancing and covenant risk, and can deter large partners or investors for longer-term projects.

International Stem Cell (ISCO) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%ISCO+6.00%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.28M
Dividend Yield
―
Average Volume (3M)
36.86K
Price to Earnings (P/E)
-2.5
Beta (1Y)
-1.09
Revenue Growth
3.40%
EPS Growth
-101.06%
Country
US
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

International Stem Cell Business Overview & Revenue Model

Company Description

International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products...

How the Company Makes Money

ISCO has historically generated revenue through multiple sources tied to its stem cell platforms: (1) sales of stem cell–related products and services (e.g., cell lines, cell-based materials, and/or contract services supporting research and developme...

International Stem Cell Financial Statement Overview

Summary

International Stem Cell's financial performance is weak, with persistent net losses, negative cash flows of -$141,000 in TTM, and high leverage (debt-to-equity ratio of 0.93). While revenue growth of 2.07% and strong gross margins of 57.9% are positives, the inability to achieve profitability and maintain liquidity drags the score down.

Income Statement

45Neutral

Balance Sheet

30Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue9.51M9.10M9.09M7.79M8.18M7.18M
Gross Profit5.22M5.07M5.32M4.61M4.91M4.24M
EBITDA-162.00K-48.00K142.00K202.00K22.00K-509.00K
Net Income-582.00K-418.00K-209.00K-131.00K-466.00K-1.04M
Balance Sheet
Total Assets5.06M4.82M5.17M5.39M5.13M4.95M
Cash, Cash Equivalents and Short-Term Investments1.09M993.00K1.23M1.59M742.00K171.00K
Total Debt3.46M3.73M3.84M4.18M4.28M4.07M
Total Liabilities4.98M8.88M9.10M5.28M9.65M9.53M
Stockholders Equity72.00K-4.06M-3.93M113.00K-4.52M-4.59M
Cash Flow
Free Cash Flow333.00K-35.00K-153.00K846.00K321.00K-1.34M
Operating Cash Flow369.00K8,00013.00K929.00K332.00K-1.30M
Investing Cash Flow-50.00K-45.00K-171.00K-83.00K-11.00K-45.00K
Financing Cash Flow-150.00K-200.00K-200.00K0250.00K824.00K

International Stem Cell Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.16

Price Trends

50DMA0.25Negative
100DMA0.27Negative
200DMA0.22Negative

Market Momentum

MACD-0.02Negative
RSI43.78Neutral
STOCH57.84Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISCO, the sentiment is Neutral. The current price of 0.16 is above the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.25, and below the 200-day MA of 0.22, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.78 is Neutral, neither overbought nor oversold. The STOCH value of 57.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ISCO.

International Stem Cell Risk Analysis

International Stem Cell disclosed 55 risk factors in its most recent earnings report. International Stem Cell reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The Transaction may not be completed on the anticipated timeline or at all.Q2, 2026
2.The announcement and pendency of the Transaction may adversely affect the Company's business relationships, operating results, and stock price.Q2, 2026
3.If the Transaction is not completed, the Company's business, financial condition, and stock price may be adversely affected.Q2, 2026

International Stem Cell Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ISCO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CELUCELU47Neutral$18.53M-0.27142.25%―-58.14%47.25%
MBIOMBIO43Neutral$2.88M-0.74-43.76%――59.14%
ISCOISCO39Underperform$1.28M-2.5419.43%―3.40%-101.06%
LGVNLGVN39Underperform$6.71M-0.24-243.26%―-18.93%39.19%
MRKRMRKR39Underperform$14.23M-1.85-64.24%―-76.50%62.83%
BRTXBRTX38Underperform$1.83M-0.06-423.84%―-8.47%25.62%

* Healthcare Sector Average

Performance Comparison

0%100%200%ISCOMRKRMBIOBRTXCELULGVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ISCO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ISCOInternational Stem Cell Corp0.160.016.00%
MRKRMarker Therapeutics0.85-0.14-14.19%
MBIOMustang Bio0.38-0.77-66.96%
BRTXBiorestorative Therapies, Inc.1.32-20.88-94.03%
CELUCelularity Inc.0.48-1.23-71.75%
LGVNLongeveron Inc.1.92-4.11-68.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Mar 31, 2026